Abstract
Biogen and Ginkgo Bioworks will collaborate on a method of manufacturing recombinant adeno-associated virus (AAV)-based vectors for gene therapies. The partners will use Ginkgo’s mammalian cell programming platform to improve AAV-producing plasmid vectors and cell lines with the goal of accelerating Biogen’s development of gene therapies. Biogen will pay Ginkgo $5 million up front and up to $115 million in commercial milestone payments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
